Skip to content

Celyad Oncology

Active Public limited companyfounded 2007active for 19 yearsRue Emile Francqui 6, 1435 Mont-Saint-GuibertKBO/BCE: BE 0891.118.115 subsidiary of #7 employer in Walloon Brabant, Research and development sector

Board

10 directors, 1 in day-to-day management, 2 auditors, last change in January 2026
Chair of the board and director, permanent representative
appointed by deed of 11-01-2024
also on the board of 4 other companies
1 other company bankrupt
Director
current term since 05-05-2020 term until 20-05-2027
also on the board of 2 other companies
listed in the 2025 annual accounts, filed on 10-06-2026
1 other company bankrupt
Director, permanent representative
since 05-05-2020 term until 20-05-2027
also on the board of 8 other companies
listed in the 2025 annual accounts, filed on 10-06-2026
1 other company bankrupt
Director
appointed by deed of 23-06-2020
Director
since 17-12-2020 2-year term from 2025
listed in the 2025 annual accounts, filed on 10-06-2026
Director
since 13-01-2022 term until 20-05-2027
listed in the 2025 annual accounts, filed on 10-06-2026
Director, permanent representative
appointed by deed of 11-01-2024
Director
appointed by deed of 20-12-2023
Director
appointed by deed of 20-12-2023
Director
appointed by deed of 31-10-2025
Daily management delegate and director general, permanent representative
appointed by deed of 29-12-2025
Statutory auditor, permanent representative
appointed by deed of 30-06-2017
Show all 13 office holders
Statutory auditor
appointed by deed of 11-07-2023
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Two directors jointly, or a managing director alone
deed of 06-06-2019
Permanent representatives 4
Permanent representative, for
Permanent representative, for
appointed by deed of 11-01-2024
Permanent representative, for
appointed by deed of 29-12-2025
Permanent representative, for
appointed by deed of 25-03-2015
also on the board of 2 other companies
1 other company bankrupt

Office holders in the KBO →

Mandates through the years

13 names, the dashed line is today

Director

Non-executive director

Director, Chair of the board

Director

Director

Director

Director

Director

Director

Director

Daily management delegate and director general

Statutory auditor

Statutory auditor
LeadershipBoardEarlierRest of the term
Mandates as a list
    • Director, appointed by deed of 20-01-2009, still in office
    • Non-executive director, appointed by deed of 25-03-2015, until 09-11-2018
    • Non-executive director, appointed by deed of 25-03-2015, still in office
    • Director, from 01-06-2018 to date
    • Chair of the board, appointed by deed of 11-01-2024, still in office
    • Director, from 05-05-2020 to date
    • Director, from 17-12-2020 to date
    • Director, from 13-01-2022 to date
    • Director, appointed by deed of 11-01-2024, still in office
    • Director, from 14-11-2023 to date
    • Director, from 14-11-2023 to date
    • Director, from 16-09-2025 to date
    • Daily management delegate and director general, appointed by deed of 29-12-2025, still in office
    • Statutory auditor, appointed by deed of 30-06-2017, still in office
    • Statutory auditor, from 05-05-2023 to date
With Starter you also see 34 former office holders in the mandate history. See the plans →

Control

Parent
US
26,191,987 voting rights
58.51%
This company
Celyad Oncology
Equity €2.2m
Loss €564,911 in 2025

and 1 other shareholder

Capital

Capital
€9,716,154.53
Shares
47,261,905
Contribution per share
€0.21
Equity per share
€0.05 in 2025
Source
deed of 31-07-2026

Owners through the years

as the annual accounts name them
58.51%
9.4%
listed until 2017
74.65% until 2016
4.6% until 2016
Owners as a list

Source: shareholder structure in its own accounts, lists of holdings in the owners' accounts

Articles of association

DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 06-06-2019 (in French)
Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 3 directors
deed of 09-06-2021 (in French)
Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
11 ter
deed of 20-01-2009 (in French)
Authorised capitalThe board may raise the capital up to this amount without a new shareholder decision.
Premier et deuxième alinéas de la présente résolution, publication aux Annexes du Moniteur belge de la décision relative aux pouvoirs nouvellement octroyés
deed of 02-08-2017 (in French)
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
20 May at 15:00
deed of 05-12-2024 (in French)

Shareholders

2 owners

Owners 2

  • USparent
    58.51%26,191,987 voting rights
  • Equity €65.7m Loss of €461,234 in 2025 (loss of €6.5m in 2024) Checked score
    Sourceown accounts 2025accounts 30-04-2025
    9.4%4,209,163 voting rights

Capital transactions

Shareholders according to the deeds
After the capital increase deed of 07-09-2017 ↗
  • €10,620,250
After the capital increase deed of 13-02-2015 ↗
  • in kind
After the capital increase deed of 22-07-2014 ↗
  • 284,090 shares
After the capital increase deed of 09-07-2014 ↗
After 7 capital increases deed of 01-12-2010 ↗
  • 14,226 shares · €1,547,282.88 in cash
  • 7,095 shares · €542,210.24 in cash
  • in cash
  • €3,069,911 in kind
  • €325,312
  • 5,678 shares · €298,509.12
  • 1,500 shares · €271,034.40
  • 7,101 shares · €108,555.20
  • 5,676 shares · €74,149.92
  • €52,474.24
  • 1,018 shares · €35,996.48
  • 5,682 shares · €200,915.52
  • 5,676 shares · €200,703.36
  • 3,549 shares · €125,492.64
  • 2,412 shares · €85,288.32
  • 3,393 shares
  • 2,493 shares
  • 900 shares
  • 2,262 shares
At incorporation deed of 06-08-2007 ↗
  • 116,569 shares (28.5%)
  • 126,193 shares (30.8%)
  • 166,613 shares (40.7%)
Capital over time
  1. 31-07-2026 Capital increase of €500,000 · to €9,716,154.53 · 2,500,000 new shares at €0.20 per share, 5.3% of the 47,261,905 shares after the increase · in cash
  2. 21-08-2025 Capital increase of €999,999.90 · to €9,216,154.53 · 3,333,333 new shares at €0.30 per share · in cash
  3. 13-05-2024 Capital reduction of €24,732,646.07 · to €8,216,154.63 · to absorb losses
  4. 29-12-2023 Capital reduction of €55,429,423.55 · to €32,948,800.70 · to absorb losses
  5. 20-12-2023 Capital increase of €7,749,999.92 · to €88,378,224.25 · 14,903,846 new shares at €0.52 per share, 36% of the 41,428,572 shares after the increase · in cash
  6. 11-09-2023 Capital increase of €2,044,000 · to €80,628,224.33 · 3,930,770 new shares at €0.52 per share, 14.8% of the 26,524,726 shares after the increase · in cash
  7. 29-12-2021 Capital increase of €22,620,000 · to €78,584,224.33 · 6,500,000 new shares · in cash
  8. 18-11-2021 Capital increase of €1,014,000 · to €55,964,224.33 · 300,000 new shares at €3.38 per share · in cash
Show 48 older capital entries
  1. 03-09-2021 Capital increase of €1,038,000 · to €54,950,224.33 · 300,000 new shares at €3.46 per share · in cash
  2. 23-08-2021 Capital increase of €1,044,000 · to €53,912,224.33 · 300,000 new shares
  3. 25-06-2021 Capital increase of €23,664 · to €52,868,224.33 · 6,800 new shares
  4. 31-05-2021 Capital increase of €633,360 · to €52,844,560.33
  5. 07-05-2021 Capital increase of €1,044,000 · to €52,211,200.33 · 300,000 new shares · in cash
  6. 15-04-2021 Capital increase of €1,044,000 · to €51,167,200.33 · 300,000 new shares
  7. 02-04-2021 Capital increase of €696,000 · to €50,123,200.33 · 200,000 new shares · in cash
  8. 20-01-2021 Capital increase of €914,585.76 · to €49,427,200.33 · 262,812 new shares · in cash
  9. 07-10-2020 Capital increase of €9,666,663.96 · to €58,179,278.53 · in cash
  10. 02-10-2019 Capital increase · 2,000,000 new shares at €9.08 per share
  11. 19-09-2019 Capital increase of €16,008,000 · to €57,560,614.57 · in cash
  12. 06-06-2019 Capital stated in the deed · €41,552,614.57 · 11,942,344 shares
  13. 25-05-2018 Capital increase of €7,203,600 · 2,070,000 new shares
  14. 24-05-2018 Capital increase of €7,308,000 · to €41,657,014.57 · in cash
  15. 28-02-2018 Capital increase of €11,880 · to €34,349,014.57 · 4,500 new shares at €2.64 per share · in cash
  16. 04-12-2017 Capital increase of €43,821.76 · to €34,337,134.57 · 5,866 new shares · “création de 5.866 nouvelles actions jouissant des mêmes droits et avantages que les actions existantes”
  17. 07-09-2017 Capital increase · 328,275 new shares · “apport d'une créance certaine,liquide et exigible”
  18. 25-08-2017 Capital increase of €20,988 · to €33,151,900.63 · 7,950 new shares at €2.64 per share
  19. 22-05-2017 Capital increase of €12,936 · to €33,130,912.63 · 4,900 new shares at €2.64 per share, 0.1% of the 9,525,753 shares after the increase
  20. 21-02-2017 Capital increase of €547,140 · to €33,117,976.63 · 207,250 new shares at €2.64 per share, 2.2% of the 9,520,853 shares after the increase · in cash
  21. 04-09-2015 Capital increase · to €32,570,836.63 · 5,916 new shares · in cash
  22. 15-07-2015 Capital increase · to €32,550,130.63
  23. 02-06-2015 Capital increase of €1,750 · to €27,440,130.63 · 500 new shares
  24. 25-03-2015 Capital increase of €2,496,830 · to €27,438,380.63
  25. 26-02-2015 Capital increase of €1,165.50 · to €24,941,550.63 · 333 new shares · in cash
  26. 13-02-2015 Capital increase of €325,804.50 · to €24,940,385.13 · 93,087 new shares, 1.3% of the 7,133,474 shares after the increase · in kind
  27. 28-11-2014 Capital increase of €17,500 · to €24,614,580.63 · 5,000 new shares
  28. 25-08-2014 Capital increase of €20,125 · to €24,597,080.63 · 5,750 new shares · in cash
  29. 22-07-2014 Capital increase · 284,090 new shares
  30. 09-07-2014 Capital increase of €12,499,960 · 284,090 new shares at €44 per share · in cash
  31. 05-06-2014 Capital increase · to €22,588,325.63 · 6,461,457 new shares
  32. 21-02-2014 Capital increase of €442,046.50 · to €22,580,054.43
  33. 16-08-2013 Capital increase · to €22,138,007.93
  34. 26-07-2013 Capital increase of €4,835,250 · to €21,412,720.43 · 1,381,500 new shares, 22.6% of the 6,125,567 shares after the increase
  35. 24-06-2013 Capital increase of €24,091.76 · to €16,577,470.43 · 2,409,176 new shares at €0.01 per share · in cash
  36. 20-06-2013 Capital increase of €1,552,729.26 · to €16,553,378.67 · 219,016 new shares
  37. 05-06-2013 Capital increase of €5,026,142 · to €15,000,649.41 · 905,357 new shares
  38. 05-06-2013 Capital increase of €24,336.18
  39. 21-03-2013 Capital increase of €632,800
  40. 06-06-2011 Capital reduction of €18,925,474.35 · to €9,974,507.41 · to absorb losses
  41. 01-12-2010 Capital increase of €471,240 · to €17,270,414.52 · 21,000 new shares at €22.44 per share · in cash
  42. 01-12-2010 Capital increase of €3,069,911 · to €20,340,325.52 · 69,455 new shares at €44.20 per share · in kind
  43. 01-12-2010 Capital increase of €5,274,403.68 · to €25,614,729.20 · 149,163 new shares at €35.36 per share · in kind
  44. 01-12-2010 Capital increase of €2,018,879.20 · 57,095 new shares at €35.36 per share
  45. 01-12-2010 Capital increase of €2,609,320.48 · to €28,224,049.68 · 73,793 new shares at €35.36 per share · in cash
  46. 01-12-2010 Capital increase of €399,921.60 · to €28,623,971.28 · 9,048 new shares at €44.20 per share · in cash
  47. 01-12-2010 Capital increase of €276,012 · to €28,899,983.28
  48. 06-08-2007 Incorporation · €62,500 · 409,375 shares

The directors' other companies

3 current directors with another company that went bankrupt, was dissolved or struck off

1 other company of this director went bankrupt (2026).

  • bankruptcy on 22-10-2026appointed in 2014, in office until the bankruptcy

1 other company of this director went bankrupt (2026).

  • bankruptcy on 20-04-2026mandate 2010 to 2022

1 other company of this director went bankrupt (2026).

  • bankruptcy on 20-04-2026appointed in 2014, in office until the bankruptcy

Source: Belgian Official Gazette (bankruptcies, judicial dissolutions, board mandates), FPS Economy (strike-offs) and the KBO register. A bankruptcy, dissolution or strike-off says nothing about the director's part in it.

Next steps